Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer

Purpose: Low-dose CT screening can reduce lung cancer–related mortality. However, CT screening has an FDR of nearly 96%. We sought to assess whether urine samples can be a source for DNA methylation–based detection of non–small cell lung cancer (NSCLC). Experimental Design: This nested case–control study of subjects with suspicious nodules on CT imaging obtained plasma and urine samples preoperatively. Cases (n = 74) had pathologic confirmation of NSCLC. Controls (n = 27) had a noncancer diagnosis. We detected promoter methylation in plasma and urine samples using methylation on beads and quantitative methylation–specific real-time PCR for cancer-specific genes (CDO1, TAC1, HOXA7, HOXA9, SOX17, and ZFP42). Results: DNA methylation at cancer-specific loci was detected in both plasma and urine, and was more frequent in patients with cancer compared with controls for all six genes in plasma and in CDO1, TAC1, HOXA9, and SOX17 in urine. Univariate and multivariate logistic regression analysis showed that methylation detection in each one of six genes in plasma and CDO1, TAC1, HOXA9, and SOX17 in urine were significantly associated with the diagnosis of NSCLC, independent of age, race, and smoking pack-years. When methylation was detected for three or more genes in both plasma and urine, the sensitivity and specificity for lung cancer diagnosis were 73% and 92%, respectively. Conclusions: DNA methylation–based biomarkers in plasma and urine could be useful as an adjunct to CT screening to guide decision-making regarding further invasive procedures in patients with pulmonary nodules.

[1]  J. Herman,et al.  Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules , 2020, Clinical Epigenetics.

[2]  A. Jemal,et al.  Cancer statistics for African Americans, 2019 , 2019, CA: a cancer journal for clinicians.

[3]  E. Dharaiya,et al.  Vancouver Risk Calculator Compared with ACR Lung-RADS in Predicting Malignancy: Analysis of the National Lung Screening Trial. , 2019, Radiology.

[4]  J. Herman,et al.  Facile profiling of molecular heterogeneity by microfluidic digital melt , 2018, Science Advances.

[5]  Renato Martins,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  Kathleen A Cronin,et al.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.

[7]  S. J. Henley,et al.  Lung cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.

[8]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[9]  Jordan H. Garst,et al.  Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. , 2017, Lung cancer.

[10]  M. Erlander,et al.  Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine , 2017, Clinical Cancer Research.

[11]  S. Datta,et al.  Implementation of Lung Cancer Screening in the Veterans Health Administration , 2017, JAMA internal medicine.

[12]  Lynne Penberthy,et al.  Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992–2013 , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[13]  H. Brenner,et al.  Smoking-associated DNA methylation markers predict lung cancer incidence , 2016, Clinical Epigenetics.

[14]  J. Herman,et al.  Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum , 2016, Clinical Cancer Research.

[15]  M. Erlander,et al.  A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Jordan H. Garst,et al.  Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer , 2016, Experimental Hematology & Oncology.

[17]  Kassandra I. Alcaraz,et al.  Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities , 2016, CA: a cancer journal for clinicians.

[18]  H. Brenner,et al.  Tobacco smoking and methylation of genes related to lung cancer development , 2016, Oncotarget.

[19]  J. Herman,et al.  DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies , 2015, Nucleic acids research.

[20]  G. Silvestri,et al.  A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. , 2015, The New England journal of medicine.

[21]  E. Kazerooni,et al.  Performance of Lung-RADS in the National Lung Screening Trial , 2015, Annals of Internal Medicine.

[22]  Fenghai Duan,et al.  Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination. , 2014, Journal of the National Cancer Institute.

[23]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[24]  J. Herman,et al.  Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer , 2014, Clinical Cancer Research.

[25]  Tza-Huei Wang,et al.  Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[26]  J. Millholland,et al.  Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing , 2012, Research and reports in urology.

[27]  J. Herman,et al.  Defining a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment , 2012, Clinical Cancer Research.

[28]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[29]  W. Rom,et al.  Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR , 2010, Clinical Cancer Research.

[30]  Yi Zhang,et al.  Single-tube analysis of DNA methylation with silica superparamagnetic beads. , 2010, Clinical chemistry.

[31]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[32]  J. Herman,et al.  Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter , 2007, Oncogene.

[33]  J. Herman,et al.  Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. , 2006, Cancer research.

[34]  F. Gilliland,et al.  Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk , 2005, Clinical Cancer Research.

[35]  S. Belinsky,et al.  Gene-promoter hypermethylation as a biomarker in lung cancer , 2004, Nature Reviews Cancer.

[36]  J. Califano,et al.  Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer , 2004, Cancer Research.

[37]  S. Syngal,et al.  Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. , 2004, The Journal of molecular diagnostics : JMD.

[38]  T. Byers,et al.  Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  F. Gilliland,et al.  Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. , 2003, Cancer research.

[40]  Colin B Begg,et al.  Survival of blacks and whites after a cancer diagnosis. , 2002, JAMA.

[41]  J. Holland,et al.  Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. , 2002, Journal of the National Cancer Institute.

[42]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[43]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[44]  T. Petty,et al.  Efficacy of Two Sputum Collection Techniques in Patients with Air Flow Obstruction , 1999, Acta Cytologica.

[45]  J. Herman,et al.  Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.

[46]  Y. Miller,et al.  Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. , 1996, Cancer research.

[47]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[48]  Frank C. Detterbeck,et al.  The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.